Anticoagulation Therapy for Deep Vein Thrombosis

Primary Treatment Phase

The American College of Chest Physicians recommends that all patients with acute DVT receive therapeutic anticoagulation, not aspirin, for the first 3-6 months 1, 2
Direct oral anticoagulants (DOACs) such as rivaroxaban or apixaban are first-line agents for DVT treatment, with a high strength of evidence 2
Aspirin has no role in acute DVT management and would result in treatment failure, according to the American Society of Hematology 1, 3

The American College of Chest Physicians strongly recommends extended anticoagulation over aspirin for patients with unprovoked DVT or persistent risk factors, including clotting disorders 1, 2
Aspirin increases recurrent PE risk 3-fold (RR 3.10; 95% CI 1.24-7.73) and recurrent DVT risk 3-fold (RR 3.15; 95% CI 1.50-6.63) compared to continued anticoagulation, based on high-quality evidence 1
Reduced-dose DOACs prevent 39 additional recurrent VTE events per 1,000 patients over 2-4 years compared to aspirin, with only 4 additional major bleeding events per 1,000 patients, according to the American College of Chest Physicians 3

The American College of Chest Physicians recommends using reduced-dose DOACs for extended prevention rather than full-dose or aspirin, with a moderate strength of evidence 2, 3
Rivaroxaban 10 mg once daily is superior to aspirin 100 mg with HR 0.26; 95% CI 0.14-0.47, according to the American Society of Hematology 1
Apixaban 2.5 mg twice daily provides better VTE protection than aspirin without significantly increasing bleeding risk, based on moderate-quality evidence 2, 3

Patients with inherited or acquired thrombophilias (clotting disorders) have unprovoked VTE by definition and require indefinite anticoagulation, according to the American College of Chest Physicians 2
The decision for extended anticoagulation should be reassessed at least annually, with a low strength of evidence 2, 4
Bleeding risk assessment is essential but should not automatically preclude extended therapy in patients with low-to-moderate bleeding risk, based on high-quality evidence 1, 2

Never substitute aspirin for anticoagulation in acute DVT treatment, as this leads to treatment failure and recurrent VTE, according to the American Society of Hematology 1, 3
Do not stop anticoagulation at 3 months in patients with clotting disorders, as they require extended therapy, with a high strength of evidence 2
Avoid using aspirin as a "compromise" between full anticoagulation and nothing, as reduced-dose DOACs are the appropriate middle ground, based on moderate-quality evidence 2, 3

In patients who are already on aspirin for cardiovascular disease and are diagnosed with acute pulmonary embolism or deep‑vein thrombosis, aspirin should be discontinued while therapeutic anticoagulation is administered, because continuation raises the risk of major bleeding (relative risk ≈ 1.26) without adding benefit. 5

Aspirin is recommended only for VTE prophylaxis after major orthopedic surgery (hip or knee replacement); it is intended for primary prevention in these surgical patients and is not appropriate for treatment of an established acute PE or DVT. 6